Cell and Gene Therapy

Rett syndrome: advances in gene therapy brings hope

Published March. 26. 2024
CGT Banner -Rett syndrome

The FDA approved trofinetide about a year ago as the first drug for treating Rett syndrome, a rare genetic disorder caused by mutations in the MECP2 gene. Researchers in Shanghai, China are exploring a novel gene therapy approach for Rett syndrome using direct injection of normal MECP2 genes enclosed in a viral vector. Unlike traditional methods, this approach aims to avoid liver toxicity and reduce costs by skipping cell alteration in a lab. Initial experiments in mice show promising results, with increased protein levels in the brain, although some regions responded better than others. This innovative approach holds potential for developing a more affordable gene therapy option fr Rett syndrome patients

https://www.labiotech.eu/in-depth/gene-therapy-rett-syndrome-treatment/ 

Get the free newsletter

Subscribe to IMAPAC for top news, trends & analysis

Download Brochure Sample


    Subscribe To Our Mailing List
    By checking the box, you acknowlege and agree to IMAPAC's Term of Service and to use your contact information provided to communicate with about offerings by IMAPAC, its brands, affliates and/or third-party partners consistent with IMAPAC's Privacy Policy..